Modeling Pharmacokinetic Profiles for Assessment of Anti-Cancer Drug on a Microfluidic System

被引:8
|
作者
Guo, Yaqiong [1 ,2 ]
Deng, Pengwei [1 ,2 ]
Chen, Wenwen [1 ,2 ]
Li, Zhongyu [1 ,3 ]
机构
[1] Chinese Acad Sci, Dalian Inst Chem Phys, Div Biotechnol, CAS Key Lab Separat Sci Analyt Chem, Dalian 116023, Peoples R China
[2] Univ Chinese Acad Sci, Beijing 100190, Peoples R China
[3] Dalian Minzu Univ, Coll Life Sci, Dalian 116600, Peoples R China
基金
中国博士后科学基金; 中国国家自然科学基金;
关键词
microfluidics; intestine; drug; pharmacokinetic (PK) profile; CHIP; METABOLISM; ORGANS; TOXICITY; PLATFORM; TISSUES; CELLS;
D O I
10.3390/mi11060551
中图分类号
O65 [分析化学];
学科分类号
070302 ; 081704 ;
摘要
The pharmacokinetic (PK) properties of drug, which include drug absorption and excretion, play an important role in determining the in vivo pharmaceutical activity. However, current in vitro systems that model PK profiles are often limited by the in vivo-like concentration profile of a drug. Herein, we present a perfused and multi-layered microfluidic chip system to model the PK profile of anti-cancer drug 5-FU in vitro. The chip device contains two layers of culture channels sandwiched by a porous membrane, which allows for drug exposure and diffusion between the two channels. The integration of upper intestine cells (Caco-2) and bottom targeted cells within the device enables the generation of loading and clearance portions of a PK curve under peristaltic flow. Fluorescein as a test molecule was initially used to generate a concentration-time curve, investigating the effects of parameters of flow rate, administration time, and initial concentration on dynamic drug concentration profiles. Furthermore, anti-cancer drug 5-FU was performed to assess its pharmaceutical activity on target cells (human lung adenocarcinoma cells or human pulmonary alveolar epithelial cells) using different drug administration regimens. A dynamic, in vivo-like 5-FU exposure refers to PK profile regimen, led to generate a lower drug concentration (dynamically fluctuate from 0 to 1 mu g/mL affected by absorption) compared to the constant exposure. Moreover, the PK profile regimen alleviates the drug-induced cytotoxicity on target cells. These results demonstrate the feasibility of determining the PK profiles using this microfluidic system with in vivo-like drug administration regimens. This established system may provide a powerful platform for the prediction of drug safety and effectiveness in the pharmaceutical research.
引用
收藏
页数:14
相关论文
共 50 条
  • [1] Controlled pharmacokinetic anti-cancer drug concentration profiles lead to growth inhibition of colorectal cancer cells in a microfluidic device
    Komen, Job
    Westerbeek, Eiko Y.
    Kolkman, Ruben W.
    Roesthuis, Julia
    Lievens, Caroline
    van den Berg, Albert
    van der Meer, Andries D.
    LAB ON A CHIP, 2020, 20 (17) : 3167 - 3178
  • [2] Anti-Cancer Drug Screening with Microfluidic Technology
    Monjezi, Mojdeh
    Rismanian, Milad
    Jamaati, Hamidreza
    Kashaninejad, Navid
    APPLIED SCIENCES-BASEL, 2021, 11 (20):
  • [3] Pharmacokinetic evaluation of a novel anti-cancer drug
    Donnarumma, F.
    Greilberger, J.
    Matzi, V.
    Lindenmann, J.
    Maier, A.
    Leis, H. -J.
    Wintersteiger, R.
    INTERNATIONAL JOURNAL OF CLINICAL PHARMACY, 2011, 33 (02) : 320 - 320
  • [4] Optimal Anti-cancer Drug Profiles for Effective Penetration of the Anti-cancer Drug Market by Generic Drugs in Japan
    Shoyo Shibata
    Maiko Matsushita
    Yoshimasa Saito
    Takeshi Suzuki
    Therapeutic Innovation & Regulatory Science, 2018, 52 : 442 - 448
  • [5] Optimal Anti-cancer Drug Profiles for Effective Penetration of the Anti-cancer Drug Market by Generic Drugs in Japan
    Shibata, Shoyo
    Matsushita, Maiko
    Saito, Yoshimasa
    Suzuki, Takeshi
    THERAPEUTIC INNOVATION & REGULATORY SCIENCE, 2018, 52 (04) : 442 - 448
  • [6] Anti-Cancer Drug Delivery System
    Li Yan
    Huang Wei
    Huang Ping
    Zhu Xinyuan
    Yan Deyue
    PROGRESS IN CHEMISTRY, 2014, 26 (08) : 1395 - 1408
  • [7] Microfluidic modelling of the tumor microenvironment for anti-cancer drug development
    Shang, Menglin
    Soon, Ren Hao
    Lim, Chwee Teck
    Khoo, Bee Luan
    Han, Jongyoon
    LAB ON A CHIP, 2019, 19 (03) : 369 - 386
  • [8] In vitro modeling of hepatocellular carcinoma molecular subtypes for anti-cancer drug assessment
    Hadassa Hirschfield
    C Billie Bian
    Takaaki Higashi
    Shigeki Nakagawa
    Tizita Z Zeleke
    Venugopalan D Nair
    Bryan C Fuchs
    Yujin Hoshida
    Experimental & Molecular Medicine, 2018, 50 : e419 - e419
  • [9] In vitro modeling of hepatocellular carcinoma molecular subtypes for anti-cancer drug assessment
    Hirschfield, Hadassa
    Bian, C. Billie
    Higashi, Takaaki
    Nakagawa, Shigeki
    Zeleke, Tizita Z.
    Nair, Venugopalan D.
    Fuchs, Bryan C.
    Hoshida, Yujin
    EXPERIMENTAL AND MOLECULAR MEDICINE, 2018, 50 : e419 - e419
  • [10] Anti-cancer activity of human ribonuclease conjugates with enhanced pharmacokinetic profiles
    Strong, L.
    Mei, B.
    Kink, J.
    Shahan, M.
    Raines, R.
    EJC SUPPLEMENTS, 2008, 6 (12): : 110 - 110